Prothena Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Prothena Biosciences's estimated annual revenue is currently $199.8M per year.
- Prothena Biosciences's estimated revenue per employee is $1,182,012
- Prothena Biosciences's total funding is $333.1M.
- Prothena Biosciences's current valuation is $1.8B. (January 2022)
Employee Data
- Prothena Biosciences has 169 Employees.
- Prothena Biosciences grew their employee count by 28% last year.
Prothena Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 150% | N/A | N/A |
#5 | $1.4M | 9 | 0% | N/A | N/A |
#6 | N/A | 7 | 40% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.5M | 12 | 9% | N/A | N/A |
What Is Prothena Biosciences?
Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003). Our lead program, NEOD001, is in a global Phase 3 registration clinical trial ? The VITAL Amyloidosis Study. There is also an on-going Phase 1/2 trial. PRX002 is in a Phase 1 multiple ascending dose clinical trial, and PRX003 is in a Phase 1 single ascending dose clinical trial. Prothena's team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prior to December 2012, Prothena's business operated as part of Elan Corporation, plc. Prothena's business consists of a substantial portion of Elan's former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan's stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol ?PRTA?? on December 21, 2012.
keywords:N/A
$333.1M
Total Funding
169
Number of Employees
$199.8M
Revenue (est)
28%
Employee Growth %
$1.8B
Valuation
N/A
Accelerator
Prothena Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Global Head Quality | |
2 | Senior Medical Director, Medical Affairs, Neuroscience | |
3 | SVP Portfolio and Alliance Management | |
4 | Senior Director Biostatistics | |
5 | Scientist II | |
6 | Director, Regulatory Operations | |
7 | Manager, Regulatory Operations | |
8 | GL Accountant | |
9 | VP, Head Clinical Biomarkers | |
10 | Director Data Management |
Prothena Biosciences News
She has served as an executive vice president at Edelman, and has also held global roles at Elan Pharmaceuticals, Prothena Biosciences,...
52980 Development of a Dual Aβ-Tau Vaccine for the Prevention of Alzheimer Disease Robin Barbour, Abderrahman Elmaarouf, Andriani Ioannou, LeeAnn Louie, Heather Prill, Michael Skov, Stephen Tam, Clara Tourino, Brian Campbell, Gene G. Kinney, Wagner Zago Prothena Biosciences Inc, South San Fra ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27.4M | 172 | N/A | N/A |
#2 | $33.7M | 174 | -8% | $278.1M |
#3 | $76.7M | 176 | -32% | $420.4M |
#4 | $23.4M | 178 | 11% | $319.7M |
#5 | $60.7M | 181 | 1% | N/A |